Dyspnea (breathlessness) in amyotrophic lateral sclerosis/motor neuron disease: prevalence, progression, severity, and correlates

References

• American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med. 1999;159:321–40.
   PubMed Web of Science ®Google Scholar
• Gysels MH, Higginson IJ. The lived experience of breathlessness and its implications for care: a qualitative comparison in cancer, COPD, heart failure and MND. BMC Palliat Care. 2011;10:15.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, van den Berg LH, Lu Y. Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF). J Neurol Neurosurg Psychiatry. 2022;93:539–46.
   PubMed Web of Science ®Google Scholar
• Helleman J, Kruitwagen-van Reenen ET, Bakers J, Kruithof WJ, van Groenestijn AC, Jaspers Focks RJH, et al. Using patient-reported symptoms of dyspnea for screening reduced respiratory function in patients with motor neuron diseases. J Neurol. 2020;267:3310–8.
   PubMed Web of Science ®Google Scholar
• Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An Official American Thoracic Society Statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185:435–52.
   PubMed Web of Science ®Google Scholar
• Bausewein C, Farquhar M, Booth S, Gysels M, Higginson I. Measurement of breathlessness in advanced disease: a systematic review. Respir Med. 2007;101:399–410.
   PubMed Web of Science ®Google Scholar
• Franchignoni F, Mandrioli J, Giordano A, Ferro S, ERRALS Group. A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:331–7.
   PubMed Web of Science ®Google Scholar
• Bakker LA, Schröder CD, van Es MA, Westers P, Visser-Meily JMA, van den Berg LH. Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model. J Neurol. 2017;264:1413–20.
   PubMed Web of Science ®Google Scholar
• Vogt S, Petri S, Dengler R, Heinze HJ, Vielhaber S. Dyspnea in amyotrophic lateral sclerosis: Rasch-based development and validation of a patient-reported outcome (DALS-15). J Pain Symptom Manage. 2018;56:736–45.e2.
   PubMed Web of Science ®Google Scholar
• Heiman-Patterson TD, Sherman MS, Yu D, Jackson CE, George A, Kasarskis EJ, Nutrition/NIV Study Group. Use of a new ALS specific respiratory questionnaire: the ARES score. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:48–53.
   PubMed Web of Science ®Google Scholar
• Banzett RB, O'Donnell CR, Guilfoyle TE, Parshall MB, Schwartzstein RM, Meek PM, et al. Multidimensional dyspnea profile: an instrument for clinical and laboratory research. Eur Respir J. 2015;45:1681–91.
   PubMed Web of Science ®Google Scholar
• Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax. 2010;65:21–6.
   PubMed Web of Science ®Google Scholar
• Williams MT, Lewthwaite H, Paquet C, Johnston K, Olsson M, Belo LF, et al. Dyspnoea-12 and multidimensional dyspnea profile: systematic review of use and properties. J Pain Symptom Manage. 2022;63:e75–87.
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Yorke J, Sprunger DB, Swearingen C, Pincus T, du Bois RM, et al. Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. Respir Med. 2010;104:1350–5.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Hagell P, Westergren A. Sample size and statistical conclusions from tests of fit to the Rasch model according to the Rasch unidimensional measurement model (RUMM) program in health outcome measurement. J Appl Meas. 2016;17:416–31.
   PubMedGoogle Scholar
• Müller M. Item fit statistics for Rasch analysis: can we trust them? J Stat Distrib Appl. 2020;7:5.
   Google Scholar
• Yorke J, Horton M, Jones PW. A critique of Rasch analysis using the Dyspnoea-12 as an illustrative example. J Adv Nurs. 2012;68:191–8.
   PubMed Web of Science ®Google Scholar
• Gibbons CJ, Mills RJ, Thornton EW, Ealing J, Mitchell JD, Shaw PJ, et al. Development of a patient reported outcome measure for fatigue in motor neurone disease: the Neurological Fatigue Index (NFI-MND). Health Qual Life Outcomes. 2011;9:101.
   PubMed Web of Science ®Google Scholar
• Gibbons CJ, Mills RJ, Thornton EW, Ealing J, Mitchell JD, Shaw PJ, et al. Rasch analysis of the Hospital Anxiety and Depression Scale (HADS) for use in motor neurone disease. Health Qual Life Outcomes. 2011;9:82–90.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS Functional Rating Scale that incorporates assessments of respiratory function. BDNF ALS Study Group (phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Young CA, Ealing J, McDermott CJ, Williams TL, Al-Chalabi A, Majeed T, et al. Measuring disability in amyotrophic lateral sclerosis/motor neuron disease: the WHODAS 2.0-36, WHODAS 2.0-32, and WHODAS 2.0-12. Amyotroph Lateral Scler Frontotemporal Degener. 2022;24:63–70.
   PubMed Web of Science ®Google Scholar
• Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.
   PubMed Web of Science ®Google Scholar
• Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27:7–22.
   PubMed Web of Science ®Google Scholar
• Schwarzer R, Jerusalem M. Generalised Self-Efficacy Scale. In: Weinman J, Wright S, Johnston M, editors. Measures in health psychology: a user’s portfolio causal and control beliefs. Windsor (UK): NFER-NELSON; 1995:35–7.
   Google Scholar
• Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28:487–95.
   PubMed Web of Science ®Google Scholar
• Gibbons CJ, Thornton EW, Ealing J, Shaw PJ, Talbot K, Tennant A, et al. Assessing social isolation in motor neurone disease: a Rasch analysis of the MND Social Withdrawal Scale. J Neurol Sci. 2013;334:112–8.
   PubMed Web of Science ®Google Scholar
• Schlüter DK, Tennant A, Mills R, Diggle PJ, Young CA. Risk factors for social withdrawal in amyotrophic lateral sclerosis/motor neurone disease. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:591–8.
   PubMed Web of Science ®Google Scholar
• Molina Y, Choi SW, Cella D, Rao D. The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): development, validation and use across neurological conditions. Int J Behav Med. 2013;20:450–60.
   PubMed Web of Science ®Google Scholar
• Young CA, Mills R, Al-Chalabi A, Burke G, Chandran S, Dick DJ, et al. Measuring quality of life in ALS/MND: validation of the WHOQOL-BREF. Amyotroph Lateral Scler Frontotemporal Degener. 2020;2020:1–9.
   Google Scholar
• Rasch G. Probabilistic models for some intelligence and attainment tests. Chicago: University of Chicago Press; 1960.
   Google Scholar
• Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273:59–65.
   PubMed Web of Science ®Google Scholar
• Jones BL, Nagin DS. A note on a Stata plugin for estimating group-based trajectory models. Sociol Methods Res. 2013;42:608–13.
   Web of Science ®Google Scholar
• Terwee CB, Peipert JD, Chapman R, Lai JS, Terluin B, Cella D, et al. Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures. Qual Life Res. 2021;30:2729–54.
   PubMed Web of Science ®Google Scholar
• Ørnbjerg LM, Christensen KB, Tennant A, Hetland ML. Validation and assessment of minimally clinically important difference of the unadjusted Health Assessment Questionnaire in a Danish cohort: uncovering ordinal bias. Scand J Rheumatol. 2020;49:1–7.
   PubMed Web of Science ®Google Scholar
• Grosbois JM, Gephine S, Kyheng M, Henguelle J, Le Rouzic O, Saey D, et al. Physical and affective components of dyspnoea are improved by pulmonary rehabilitation in COPD. BMJ Open Respir Res. 2022;9:e001160.
   PubMed Web of Science ®Google Scholar
• Simsic AA, Yorke J, Regueiro EG, Di Lorenzo VP, Baddini-Martinez J. Validation of the Dyspnoea-12 Scale into Portuguese speaking COPD patients. Clin Respir J. 2018;12:1942–8.
   PubMed Web of Science ®Google Scholar
• Sundh J, Bornefalk H, Sköld CM, Janson C, Blomberg A, Sandberg J, et al. Clinical validation of the Swedish version of Dyspnoea-12 instrument in outpatients with cardiorespiratory disease. BMJ Open Respir Res. 2019;6:e000418.
   PubMed Web of Science ®Google Scholar
• Nishimura K, Oga T, Nakayasu K, Taniguchi H, Ogawa T, Watanabe F, et al. Comparison between tools for measuring breathlessness: cross-sectional validation of the Japanese version of the Dyspnoea-12. Clin Respir J. 2021;15:1201–9.
   PubMed Web of Science ®Google Scholar
• Ekström M, Bornefalk H, Sköld CM, Janson C, Blomberg A, Sandberg J, et al. Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2 weeks and 6 months: follow-up of a longitudinal clinical study. Eur Respir J. 2021;57:2002823.
   PubMed Web of Science ®Google Scholar
• Wyrwich KW, Norman GR. The challenges inherent with anchor-based approaches to the interpretation of important change in clinical outcome assessments. Qual Life Res. 2023;32:1239–46.
   PubMed Web of Science ®Google Scholar
• Grønseth R, Vollmer WM, Hardie JA, Ólafsdóttir IS, Lamprecht B, Buist AS, et al. Predictors of dyspnoea prevalence: results from the BOLD study. Eur Respir J. 2014;43:1610–20.
   PubMed Web of Science ®Google Scholar
• NICE. Motor neurone disease: assessment and management. In: Centre NCG, editor. London: National Institute for Health and Care Excellence; 2016.
   Google Scholar